{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:02:19Z","timestamp":1788109339414,"version":"build-2803163510"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Beginning in 2005, the US implemented routine immunization of adolescents with a quadrivalent conjugate vaccine (MenACWY) for the prevention of invasive meningococcal disease (IMD).<\/jats:p><\/jats:sec>Objectives<\/jats:title>To assess whether MenACWY immunization was associated with a reduced IMD burden among the US adolescent population and how the downward trajectory of IMD that began in the mid-1990s might have evolved in the absence of vaccination efforts.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this decision analytical study, a bayesian hierarchical Poisson regression model was developed to investigate the potential trajectory of IMD among US adolescents and young adults without vaccination and evaluate the direct association of vaccination with IMD burden. The model included the entire age-stratified US population and was fitted to national incidence data for serogroups C, W, and Y from January 1, 2001, to December 31, 2021, with stratification by vaccination status for IMD cases.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Simulated counterfactual scenario of absent vaccination from 2005 to 2021, while retaining the incidence rate of IMD for unvaccinated individuals estimated during model fitting.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcomes were the estimated numbers of IMD cases and deaths averted by MenACWY vaccination among US adolescents and young adults aged 11 to 23 years.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the entire US population from 2005 to 2021, MenACWY vaccination prevented an estimated 172 (95% credible interval [CrI], 85-345) cases of IMD among US adolescents 11 to 15 years of age and 328 (95% CrI, 164-646) cases of IMD among those aged 16 to 23 years. Absent vaccination, the cumulative incidence of IMD in these age groups would have been at least 59% higher than reported over the same period with vaccination. Using case fatality rates of unvaccinated individuals derived from national data, vaccination averted an estimated 16 (95% CrI, 8-31) deaths among adolescents aged 11 to 15 years and 38 (95% CrI, 19-75) deaths among those aged 16 to 23 years.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This decision analytical model suggests that the MenACWY vaccination program in the US was associated with a reduced burden of meningococcal disease. Without vaccination, the incidence rates per 100\u202f000 adolescents and young adults would have been substantially higher than those observed during the vaccine era.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.43551","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T16:01:00Z","timestamp":1730908860000},"page":"e2443551","source":"Crossref","is-referenced-by-count":9,"title":["Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults"],"prefix":"10.1001","volume":"7","author":[{"given":"Thomas","family":"Shin","sequence":"first","affiliation":[{"name":"Health Economics and Outcomes Research, Sanofi, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad R.","family":"Wells","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Affan","family":"Shoukat","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics, University of Regina, Regina, Saskatchewan, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Potter-Schwartz","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Langevin","sequence":"additional","affiliation":[{"name":"Health Economics and Value Assessment, Sanofi, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Langley","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison P.","family":"Galvani","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed M.","family":"Moghadas","sequence":"additional","affiliation":[{"name":"Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"zoi241243r1","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae.","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"zoi241243r2","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1186\/s12889-022-13342-2","article-title":"Range of invasive meningococcal disease sequelae and health economic application\u2014a systematic and clinical review.","volume":"22","author":"Shen","year":"2022","journal-title":"BMC Public Health"},{"issue":"12","key":"zoi241243r3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis.","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"zoi241243r4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","article-title":"The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination.","volume":"81","author":"Parikh","year":"2020","journal-title":"J Infect"},{"issue":"220","key":"zoi241243r5","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1093\/infdis\/jiz358","article-title":"Bacterial meningitis epidemiology in five countries in the meningitis belt of sub-Saharan Africa, 2015-2017.","volume":"220","author":"Soeters","year":"2019","journal-title":"J Infect Dis"},{"issue":"1","key":"zoi241243r6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease.","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"issue":"9","key":"zoi241243r7","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.3201\/eid1809.120257","article-title":"Trends in meningococcal disease in the United States military, 1971-2010.","volume":"18","author":"Broderick","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"zoi241243r8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1086\/315158","article-title":"The changing epidemiology of meningococcal disease in the United States, 1992-1996.","volume":"180","author":"Rosenstein","year":"1999","journal-title":"J Infect Dis"},{"issue":"RR-2","key":"zoi241243r9","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"zoi241243r10","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines\u2014Advisory Committee on Immunization Practices (ACIP), 2010.","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"zoi241243r12","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2193","article-title":"Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine.","volume":"139","author":"Cohn","year":"2017","journal-title":"Pediatrics"},{"issue":"9","key":"zoi241243r13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamapediatrics.2020.1990","article-title":"Incidence of meningococcal disease before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States.","volume":"174","author":"Mbaeyi","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"6","key":"zoi241243r14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/EDE.0000000000001664","article-title":"Conditional poisson regression with random effects for the analysis of multi-site time series studies.","volume":"34","author":"Barrera-G\u00f3mez","year":"2023","journal-title":"Epidemiology"},{"key":"zoi241243r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpopen.2021.100063","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"3","author":"Husereau","year":"2022","journal-title":"Health Policy Open"},{"issue":"6","key":"zoi241243r17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/INF.0b013e31820a8b3c","article-title":"Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.","volume":"30","author":"Macneil","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"zoi241243r18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/1471-2334-9-175","article-title":"Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005: demand, supply and seasonality.","volume":"9","author":"Lorick","year":"2009","journal-title":"BMC Infect Dis"},{"issue":"33","key":"zoi241243r19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.15585\/mmwr.mm6733a1","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years\u2014United States, 2017.","volume":"67","author":"Walker","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"zoi241243r24","doi-asserted-by":"publisher","first-page":"1649.e1","DOI":"10.1016\/j.cmi.2022.07.004","article-title":"Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme.","volume":"28","author":"Carr","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"zoi241243r25","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40121-024-00958-7","article-title":"Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany.","volume":"13","author":"Gruhn","year":"2024","journal-title":"Infect Dis Ther"},{"key":"zoi241243r26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2458-7-130","article-title":"Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.","volume":"7","author":"Caro","year":"2007","journal-title":"BMC Public Health"},{"issue":"12","key":"zoi241243r27","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/cid\/ciab791","article-title":"Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study.","volume":"74","author":"Ohm","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"34","key":"zoi241243r28","doi-asserted-by":"publisher","first-page":"912","DOI":"10.15585\/mmwr.mm7234a3","article-title":"Vaccination coverage among adolescents aged 13-17 years\u2014national immunization survey\u2014teen, United States, 2022.","volume":"72","author":"Pingali","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi241243r29","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1186\/s12889-024-19081-w","article-title":"The impact of regional disparities on the availability of meningococcal vaccines in the US.","volume":"24","author":"Schley","year":"2024","journal-title":"BMC Public Health"},{"issue":"4","key":"zoi241243r30","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/cid\/ciy548","article-title":"Epidemiology of meningococcal disease outbreaks in the United States, 2009-2013.","volume":"68","author":"Mbaeyi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"zoi241243r11","unstructured":"Meningococcal disease: meningococcal vaccine recommendations. Centers for Disease Control and Prevention. August 21, 2024. Accessed April 8, 2024. https:\/\/www.cdc.gov\/meningococcal\/hcp\/vaccine-recommendations\/"},{"key":"zoi241243r16","unstructured":"Active Bacterial Core surveillance (ABCs): surveillance reports. Centers for Disease Control and Prevention. September 13, 2024. Accessed April 8, 2024. https:\/\/www.cdc.gov\/abcs\/reports\/?"},{"key":"zoi241243r20","unstructured":"Teen vaccination coverage publications and resources. Centers for Disease Control and Prevention. August 16, 2024. Accessed April 8, 2024. https:\/\/www.cdc.gov\/teenvaxview\/publications\/?"},{"key":"zoi241243r21","unstructured":"US population by year, race, age, ethnicity, & more. USAFacts. Accessed July 7, 2023. https:\/\/usafacts.org\/data\/topics\/people-society\/population-and-demographics\/our-changing-population\/?"},{"key":"zoi241243r22","unstructured":"US population by year. Multpl. Accessed March 2, 2024. https:\/\/www.multpl.com\/united-states-population\/table\/by-year?"},{"key":"zoi241243r23","unstructured":"ABM-Lab \/ imd_vaccine. GitHub. Accessed September 24, 2024. https:\/\/github.com\/ABM-Lab\/imd_vaccine"},{"key":"zoi241243r31","unstructured":"Schillie? S. Revising the adolescent meningococcal vaccine schedule: term of reference and considerations. February 29, 2024. Centers for Disease Control and Prevention. Accessed March 16, 2024. https:\/\/stacks.cdc.gov\/view\/cdc\/148680?"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2825811\/shin_2024_oi_241243_1730219471.30594.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T16:01:04Z","timestamp":1730908864000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2825811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.43551","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]}}}